Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2005
10/12/2005CN1222319C Composition for IVF
10/12/2005CN1222294C Combined preparations comprising morpholine anthracyclines and anticancer agent
10/12/2005CN1222291C Novel uses of combined 5-HT 1A agonists and serotonin reuptake inhibitor
10/12/2005CN1222283C Methods of rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
10/11/2005US6953858 A phenylalkyl secondary- and tertiary-amides enzyme inhibitors as viricides, for treating AIDS
10/11/2005US6953800 Quinazoline derivatives
10/11/2005US6953799 which buffer intracellular reduction and oxidation for the stressed cells in various disease states; beneficial as adjunctive support therapy
10/11/2005US6953797 Nitric oxide synthase inhibitor; antiinflammatory agents
10/11/2005US6953795 N-[5-[[3[-(morpholin-4-yl)carbonyl]phenyl]thio]thiazol-2-yl]-4-(N,N-dimethylamino)benzamide; may be combined with antiinflammatory, antiarthritic, antiproliferative, anticancer, anti-cytotoxic or antiallergenic agents
10/11/2005US6953791 Dipeptide derivatives
10/11/2005US6953786 Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
10/11/2005US6953784 Cross-linked polysaccharide drug carrier
10/11/2005US6953783 Modulation of gene expression by combination therapy
10/11/2005US6953778 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
10/11/2005US6953681 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
10/11/2005US6953679 Biosynthesis with enzyme or microorganism, catalyzing hydroxylation reaction, useful as modulators of nuclear hormone receptor, anticarcinogenic agents, immunomodulators, steroid mimic
10/11/2005US6953670 Methods for identifying compounds capable of supplementing the biological activity of leptin
10/11/2005US6953661 Method of preventing transport of a neurotropic virus and identifying agents for achieving same
10/11/2005US6953595 Inhibitors of apoptosis of nerve cells
10/11/2005US6953586 Bioabsorbable and biocompatible grafts for administered under the skin of animals comprising solid pellets having animal growth regulators such as trenbolone acetate and melengesterol acetate
10/11/2005US6953583 Use of conjugated linoleic acid (CLA) for the topical treatment of cellulite
10/11/2005US6953578 Administering a prostaglandin-2 synthase inhibitor selected from indomethacin, animoguanadine or N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide for preventing or reducing severity of autoimmune disease
10/11/2005US6953568 Administering biological conjugates that bind preferentially to endothelial protein C receptor(EPCR), to endothelial cells of vascular systems; genetic translocation; drug delivery
10/06/2005WO2005093083A1 Method of disease prediction and method of using the same
10/06/2005WO2005093082A1 Method of screening compound capable of accelerating or inhibiting apoptosis, apoptosis accelerator and apoptosis inhibitor
10/06/2005WO2005093068A1 Novel protein and promoter
10/06/2005WO2005093066A1 Marker gene for arthrorheumatism test
10/06/2005WO2005093063A1 Kit for solid cancer diagnosis and medicine for solid cancer therapy
10/06/2005WO2005093057A1 Truncated dance, dance complex and method of using these
10/06/2005WO2005093036A2 Inhibitors of siderophore biosynthesis in fungi
10/06/2005WO2005092442A2 Method and compositions for treatment of chronic neuropathic pain
10/06/2005WO2005092385A2 Combination therapy of azd2171 and a taxane
10/06/2005WO2005092384A2 Combination therapy with azd2171 and a platinum anti-tumour agent
10/06/2005WO2005092383A1 Preventive/remedy for respiratory diseases
10/06/2005WO2005092382A1 Therapeutic agent for diabetes containing insulin resistance improving agent
10/06/2005WO2005092380A2 Uses of anti-ctla-4 antibodies
10/06/2005WO2005092362A2 Pharmaceutical combined preparation containing a therapeutic protein
10/06/2005WO2005092361A1 Herbal therapy for the treatment of asthma
10/06/2005WO2005092360A1 Herbal therapy for the treatment of food allergy
10/06/2005WO2005092358A1 Oral health care drink and method for reducing malodors
10/06/2005WO2005092349A1 Insulin resistance improving agent
10/06/2005WO2005092345A1 Use of a phenothiazine derivative for preventing and/or treating hearing loss
10/06/2005WO2005092330A1 Medicament or dietary agent for oral administration containing blueberry extract and antioxidants and micronutrients
10/06/2005WO2005092321A1 Pharmaceutical composition for prevention or treatment of increased urinary frequency or involuntary urination
10/06/2005WO2005092318A1 Combinations comprising alpha-2-delta ligands
10/06/2005WO2005092306A1 Methods and compositions for modulating opioid tolerance and chronic pain
10/06/2005WO2005092303A2 Combination therapy with azd2171 and 5-fu and/or cpt-11
10/06/2005WO2005092265A1 Pasting agent
10/06/2005WO2005092264A1 Drug-enhanced adhesion prevention
10/06/2005WO2005092123A1 Solubilized coq-10 and carnitine
10/06/2005WO2005092099A1 Hiv integrase inhibitors
10/06/2005WO2005091872A2 Pharmaceutical composition and method for the transdermal delivery of magnesium
10/06/2005WO2005072893A8 Functionalized colloidal metal compositions and methods
10/06/2005WO2005063294A8 Inhibitor for the formation of ϝ-secretase complex
10/06/2005WO2005039485B1 Gsk-3 inhibitors and uses thereof
10/06/2005WO2005032477A3 Gamma-tocopherol treatment for cystic fibrosis
10/06/2005WO2004041193A3 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5
10/06/2005US20050222414 N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222273 Treatment of female sexual dysfunction
10/06/2005US20050222270 Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
10/06/2005US20050222259 Methods of activating PPAR-alpha nuclear receptors in mammals
10/06/2005US20050222250 Curcumin for the prevention and/or treatment of tissue damage
10/06/2005US20050222243 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
10/06/2005US20050222235 Drugs for improving the prognosis of brain injury and a method of screening the same
10/06/2005US20050222224 p53 Inhibitors and therapeutic use of the same
10/06/2005US20050222221 Cell differentiation, regeneration of pancreas epithelial cells to insulin producing beta cells; administering a dipeptidyl-peptidase activators
10/06/2005US20050222217 Agonists and antagonists of nicotinergic acetylcholine receptors of insects like fleas, lice and flies, on humans or animals; chloronicotinyl insecticides such as imidaclopridas veterinary medicine; collars; tags
10/06/2005US20050222215 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
10/06/2005US20050222193 Novel combination for the treatment of airway disorders
10/06/2005US20050222169 Compositions and methods of treating infections
10/06/2005US20050222155 Inhibitors of akt activity
10/06/2005US20050222137 Combination of organic compounds
10/06/2005US20050222118 For therapy of inflammatory or allergic condition
10/06/2005US20050222112 Treating psychological dependency (not physical dependancy leading towithdrawal) by administering the agonist (cortisone acetate) and the addictive drug after detoxification of the dependent-patient; highly-dosed and "imprinted"by the mixture eliminates and replaces the "addiction memory"
10/06/2005US20050222102 Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroids
10/06/2005US20050222100 Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
10/06/2005US20050222099 Pregnane steroids for use in the treatment of cns disorders
10/06/2005US20050222093 Methods for restoring cognitive function following systemic stress
10/06/2005US20050222092 Use of s1p receptor agonists in heart diseases
10/06/2005US20050222091 Use of tyrosine kinase inhibitors for treating cns disorders
10/06/2005US20050222085 Quaternised ammonium cyclodextrin compounds
10/06/2005US20050222076 Composition for cell proliferation
10/06/2005US20050222046 Pharmaceutical preparations of glutathione and methods of administration thereof
10/06/2005US20050222025 Method of inhibiting fibrosis with a somatostatin agonist
10/06/2005US20050222016 Nucleoside analogs in combination therapy of herpes simplex infections
10/06/2005US20050222014 Administering phosphodiestarase inhibitors and melanocortin receptor antagonist: synergistic mixture
10/06/2005US20050222013 Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
10/06/2005US20050222001 Stable foamed compositions
10/06/2005US20050221431 Conjugate having a polypeptide targeting moiety including a sequence of human vascular endothelial growth factor, human annexin V, fragment of anthrax lethal factor, or single chain vascular endothelial growth factor covalently bonded via a disulfide bone to a binding moiety such as an adapter protein
10/06/2005US20050221428 Chimeric neuropeptide Y receptors
10/06/2005US20050221420 Nogo receptor homologues and their use
10/06/2005US20050221391 Reagents and methods for identification of binding agents
10/06/2005US20050221368 Methods for identifying RNA binding compounds
10/06/2005US20050221355 cDNA for human methylenetetrahydrofolate reductase and uses thereof
10/06/2005US20050221347 Inhibitors of binding between proteins and macromolecular ligands
10/06/2005US20050221346 May be used to detect the presence of a cancer or to evaluate the prognosis of a known disease
10/06/2005US20050221344 Interferon-Like molecules and uses thereof
10/06/2005US20050221330 Glial cell line-derived neurotrophic factor (GDNF); nervous system disorders, autonomic nervous system, shingles, asthma, irritable bowel, inflammatory bowel, constipation, headache, arthritis, spinal cord injury, chronic back pain, hypertension, mucositis, diabetes, fibromyalgia, and wound healing
10/06/2005US20050221317 Use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
1 ... 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 ... 1151